VolitionRx raises $6.25M via convertible note, completes 1-for-20 reverse split

Filed May 14, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 15, 2025 · ~1 min read

Key Changes

• high

  Company completed 1-for-20 reverse stock split in April 2026, typically done to maintain exchange listing compliance. All share counts retroactively adjusted.

  MD&A: Capital Structure verify on EDGAR →
• high

  Secured $6.25M from Lind Global via $7.5M convertible note in May 2025, now reflected on balance sheet. Additional convertible note issued January 2026. Combined derivative liabilities total $869K at quarter-end.

  MD&A: Financing verify on EDGAR →
• high

  Net loss widened to $6.7M from $5.5M year-over-year, driven by $1.5M in non-cash debt-related charges (discount amortization and extinguishment loss). Operating loss actually improved slightly to $5.3M.

  MD&A: Results of Operations verify on EDGAR →